HRA002727
Title:
Genomic Characterization Revealed from Prospective Clinical Sequencing of 1016 Chinese Prostate Cancer Patients
Release date:
2023-02-23
Description:
It is increasingly important for clinicians involved in the management of prostate cancer to understand the relevance of acquired (somatic) mutations that occur in prostate cancer cells. In the advanced disease setting, mutations in homologous recombination repair genes (eg, BRCA1, BRCA2, ATM, CHEK2, PALB2) suggest candidacy for platinum chemotherapy and PARP inhibitor trials. Similarly, microsatellite instability and mismatch repair deficiency, which may arise in the setting of MLH1, MSH2, MSH6, and PMS2 mutations, suggest potential vulnerability to PD-1 inhibitors. Tumor-directed somatic sequencing may guide treatment decision-making.Here, we sequenced Prostate Cancer Patients in 1,016 Chinese patients .Somatic DNA was sequenced using a multigene panel, Clinical characteristics were assessed by mutation status.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
prostate cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
shca
Contact person:
Zhu Yao
Email:
yaozhu09@fudan.edu.cn
Description:
This DAC was formed by the department of urology, Fudan University Shanghai Cancer Center.
Individuals & samples
Submitter:   Zhu Yao / yaozhu09@fudan.edu.cn
Organization:   Fudan university Shanghai Cancer Center
Submission date:   2022-05-11
Requests:   2